A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018)

References

• Zarganes-Tzitzikas T, Konstantinidou M, Gao Y, et al. Inhibitors of programmed cell death 1 (PD-1): a patent review (2010–2015). Expert Opin Ther Pat. 2016;26:973–977.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company. Compounds useful as immunomodulators. WO2015/034820 A1. 2015.
   Google Scholar
• Bristol-Myers Squibb Company. Compounds useful as immunomodulators. WO2015/160641 A2.
   Google Scholar
• Zak KM, Grudnik P, Guzik K, et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget. 2016;7:30323–30335.
   PubMed Web of Science ®Google Scholar
• Guzik K, Zak KM, Grudnik P, et al. Small-molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) Interaction via transiently induced protein states and dimerization of PD-L1. J Med Chem. 2017;60:5857–5867.
   PubMed Web of Science ®Google Scholar
• Skalniak L, Zak KM, Guzik K, et al. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget. 2017;8:72167–72181.
   PubMedGoogle Scholar
• Bristol-Myers Squibb Company. 1,3-dihydroxy-phenyl derivatives useful as immunomodulators. WO2018/009505 A1. 2018.
   Google Scholar
• Bristol-Myers Squibb Company. Compounds useful as immunomodulators. WO2017/066227 A1. 2017.
   Google Scholar
• Bristol-Myers Squibb Company. Biaryl compounds useful as immunomodulators. WO2018/044963 A1. 2018.
   Google Scholar
• Arising International, LLC. Symmetric or semi-symmetric compounds useful as immunomodulators. WO2018/026971 A1. 2018.
   Google Scholar
• Polaris Pharmaceuticals, Inc. Immune checkpoint inhibitors, compositions and methods there for. WO2018/045142 A1. 2018.
   Google Scholar
• Chemocentryx, Inc. Immunomodulator compounds. WO2018/005374 A1. 2018.
   Google Scholar
• Institute of Materia Medica, Chinese Academy of Medical Sciences. Bromo benzyl ether derivative, preparation method therefor, and pharmaceutical composition and uses thereof. WO2017/202275 A1. 2017.
   Google Scholar
• Institute of Materia Medica, Chinese Academy of Medical Sciences. Benzyl phenyl ether derivative, preparation method therefor, and pharmaceutical composition and uses thereof. WO2017/202273 A1. 2017.
   Google Scholar
• Institute of Materia Medica, Chinese Academy of Medical Sciences. Phenylate derivative, preparation method therefor, and pharmaceutical composition and uses thereof. WO2017/202276 A1. 2017.
   Google Scholar
• Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof. WO2018/006795 A1. 2018.
   Google Scholar
• Maxinovel.com: maxinovel Pharmaceuticals Announces the Presentation of Its Orally Active PD-1/PD-L1 Inhibitors in 2018 AACR [Internet]. Guangzhou (China): Maxinovel Pharmaceuticals, Inc. [cited 2018 Jun 26]; Available from: http://www.maxinovel.com/en/112.html
   Google Scholar
• Aurigene Discovery Technologies Limited. 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators. WO2015/033301 A1. 2015.
   Google Scholar
• Aurigene Discovery Technologies Limited. 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators. WO2016/142852 A1. 2016.
   Google Scholar
• Aurigene Discovery Technologies Limited. 3-substituted 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators. WO2016/142894 A1. 2016.
   Google Scholar
• Aurigene Discovery Technologies Limited. 1,2,4-oxadiazole derivatives as immunomodulators. WO2015/033299 A1. 2015.
   Google Scholar
• Aurigene Discovery Technologies Limited. 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators. WO2016/142886 A2. 2016.
   Google Scholar
• Aurigene Discovery Technologies Limited. 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators WO2016/142833 A1. 2016.
   Google Scholar
• Aurigene Discovery Technologies Limited. Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators. WO2018/051255 A1. 2018.
   Google Scholar
• Aurigene Discovery Technologies Limited. Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators. WO2018/051254 A1. 2018.
   Google Scholar
• Incyte Corporation. Heterocyclic compounds as immunomodulators. WO2017/205464 A1. 2017.
   Google Scholar
• Incyte Corporation. Heterocyclic compounds as immunomodulators. US2017/0107216 A1. 2017.
   Google Scholar
• Incyte Corporation. Heterocyclic compounds as immunomodulators. WO2017/070089A1. 2017.
   Google Scholar
• Incyte Corporation. N-phenyl-pyridine-2-carboxamide derivatives and their use as PD-1/PD-L1 protein/protein interaction modulators. WO2017/106634A1. 2017.
   Google Scholar
• Incyte Corporation. Heterocyclic compounds as immunomodulators. US2017/0174679 A1. 2017.
   Google Scholar
• Incyte Corporation. Heterocyclic compounds as immunomodulators. US2018/0057486 A1. 2018.
   Google Scholar
• Incyte Corporation. Heterocyclic compounds as immunomodulators. WO2018/013789 A1. 2018.
   Google Scholar
• Incyte Corporation. Heterocyclic compounds as immunomodulators. US2017/0362253 A1. 2017.
   Google Scholar
• Incyte Corporation. Heterocyclic compounds as immunomodulators. WO2017/192961 A1. 2017.
   Google Scholar
• Rijksuniversiteit Groningen. Inhibitors of the PD-1/PD-L1 protein/protein interaction. WO2017/118762 A1. 2017.
   Google Scholar
• Aurigene Discovery Technologies Limited. Therapeutic compounds for immunomodulation. US2014/199334 A1. 2014.
   Google Scholar
• Aurigene Discovery Technologies Limited. Immunomodulating peptidomimetic derivatives. WO2015/036927 A1. 2015.
   Google Scholar
• Bristol-Myers Squibb Company. Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions. US2014/0294898 A1. 2014.
   Google Scholar
• Bristol-Myers Squibb Company. Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions. US2016/0340391 A1. 2016.
   Google Scholar
• Magiera-Mularz K, Skalniak L, Zak KM, et al. Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint. Angew Chemie - Int Ed. 2017;56:13732–13735.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company. Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions. WO2016/039749 A1. 2016.
   Google Scholar
• Bristol-Myers Squibb Company. Macrocyclic inhibitors of the PD-1/PD-L1 and CD80/PD-L1 protein/protein interactions. WO2017/176608 A1. 2017.
   Google Scholar
• Bristol-Myers Squibb Company. Macrocyclic ipeptides useful as immunomodulators. WO2016/077518 A1. 2016.
   Google Scholar
• Bristol-Myers Squibb Company. Immunomodulators. WO2016/100608 A1. 2016.
   Google Scholar
• Bristol-Myers Squibb Company. Immunomodulators. US2017/0252432 A1. 2017.
   Google Scholar
• Bristol-Myers Squibb Company. Immunomodulators. WO2016/126646 A1. 2016.
   Google Scholar
• Aurigene Discovery Technologies Limited. Therapeutic immunomodulating compounds WO2015/044900 A1. 2015.
   Google Scholar
• Aurigene Discovery Technologies Limited. Immunomodulating cyclic compounds. US2015/0125491 A1. 2015.
   Google Scholar
• Aurigene Discovery Technologies Limited. Cyclic peptidomimetic compounds as immunomodulators. WO2015/033303 A1. 2015.
   Google Scholar
• Aurigene Discovery Technologies Limited. Therapeutic cyclic compounds as immunomodulators. WO2016/142835 A1. 2016.
   Google Scholar
• Konstantinidou M, Zarganes-Tzitzikas T, Magiera-Mularz K, et al. Immune checkpoint PD-1/PD-L1: is there life beyond antibodies? Angew Chemie - Int Ed. 2018;57:4840–4848.
   PubMed Web of Science ®Google Scholar